Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
6
×
life sciences
national blog main
national top stories
new york top stories
6
×
novartis
zolgensma
6
×
biotech
boston blog main
boston top stories
fda
gene therapy
national
new york blog main
san francisco top stories
biogen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
glaxosmithkline
johnson & johnson
spinal muscular atrophy
abbvie
amgen
avexis
brian kaspar
What
roundup
bio
news
biotech
drug
fda
nash
new
past
therapy
according
age
akcea
america
approval
approved
atrophy
august
bigger
biggest
biogen
biogen’s
biopharmaceutical
busy
cases
centers
cigarettes
come
companies
continues
control
convo
convoluted
daily
days
deal
deaths
decisions
democrats
devices
Language
unset
Current search:
zolgensma
×
" new york top stories "
×
" clinical trials "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy